ArticleJournal of bacteriology2013
Activation and products of the cryptic secondary metabolite biosynthetic gene clusters by rifampin resistance (rpoB) mutations in actinomycetes.
Article in Journal of bacteriology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 113 citations in OpenAlex.
- Identification and distribution of a downregulatory signaling alkyloxazole inProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Rational construction of rpsL or/and rpoB merodiploids affects biosynthesis of secondary metabolite in Streptomyces.Molecular biology reports · 2026Article
- Integrated Transcriptomic and Proteomic Analyses Uncover the Mechanisms of Keratin Degradation inBiology · 2026Article
- Article
- Deciphering the Impact of Temperature on Pleiotropic Consequences of RNA Polymerase Mutations.Molecular biology and evolution · 2025Article
- A new antifungal compound from Streptomyces diastatochromogenes.BMC biotechnology · 2025Article
- Recent insights into actinobacteria research in antimicrobial resistance: a review.Molecular biology reports · 2025Review
- Ribosome Engineering for Enhanced Butenyl-Spinosyn Production in Saccharopolyspora pogona.Current microbiology · 2025Article
- Ribosome engineering of Myxococcus xanthus for enhancing the heterologous production of epothilones.Microbial cell factories · 2024Article
- The Daunomycin: Biosynthesis, Actions, and the Search for New Solutions to Enhance Production.Microorganisms · 2024Review
- Identification and characterization of a strong constitutive promoter stnYp for activating biosynthetic genes and producing natural products in streptomyces.Microbial cell factories · 2023Article
- Co-Expression of Transcriptional Regulators and Housekeeping Genes inMicroorganisms · 2023Article
- Properties of Multidrug-Resistant Mutants Derived from Heterologous Expression Chassis StrainMicroorganisms · 2023Article
- Comparative Proteomic Analysis of Transcriptional and Regulatory Proteins Abundances inInternational journal of molecular sciences · 2022Article
- Inducing Global Expression of Actinobacterial Biosynthetic Gene Clusters.Methods in molecular biology (Clifton, N.J.) · 2022Article
- High-Throughput Transcriptional Characterization of Regulatory Sequences from Bacterial Biosynthetic Gene Clusters.ACS synthetic biology · 2021Article
- Eliciting the silent lucensomycin biosynthetic pathway in Streptomyces cyanogenus S136 via manipulation of the global regulatory gene adpA.Scientific reports · 2021Article
- Recent Advances in Silent Gene Cluster Activation inFrontiers in bioengineering and biotechnology · 2021Review
- Anticancer Drug Discovery from Microbial Sources: The Unique Mangrove Streptomycetes.Molecules (Basel, Switzerland) · 2020Review
- Recent Advances in Strategies for Activation and Discovery/Characterization of Cryptic Biosynthetic Gene Clusters inMicroorganisms · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A subset of rifampin resistance (rpoB) mutations result in the overproduction of antibiotics in various actinomycetes, including Streptomyces, Saccharopolyspora, and Amycolatopsis, with H437Y and H437R rpoB mutations effective most frequently. Moreover, the rpoB mutations markedly activate (up to 70-fold at the transcriptional level) the cryptic/silent secondary metabolite biosynthetic gene clusters of these actinomycetes, which are not activated under general stressful conditions, with the exception of treatment with rare earth elements. Analysis of the metabolite profile demonstrated that the rpoB mutants produced many metabolites, which were not detected in the wild-type strains. This approach utilizing rifampin resistance mutations is characterized by its feasibility and potential scalability to high-throughput studies and would be useful to activate and to enhance the yields of metabolites for discovery and biochemical characterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.